FGL1 and familial pancreatic carcinoma: Our study showed that EPA treatment inhibited cell visibility and p-STAT3, HPS, and ACC-1, but not FASN expressions in KRAS-mutant SUIT-2 cells, suggesting that EPA treatment might reduce ACC-1-mediated de novo lipogenesis to downregulate the tumor growth and survival of pancreatic cancer cells.